Genomics and proteomics of pulmonary vascular disease

Mark Geraci, Barbara Meyrick

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Study of RNA and proteins in cells of both normal and diseased tissues is providing researchers with new knowledge of disease pathologies. While still in its early stages, high-throughput expression analysis is improving our understanding of the pathogenesis of pulmonary arterial hypertension (PAH). While many studies have used microarray and proteomic analyses as "hypothesisgenerating" tools, the technologies also have potential to identify and quantify biomarkers of disease. To date, many of the published studies have examined gene expression profiles of tissue biopsies, others have utilized cells from peripheral blood. Microarray technology has been employed successfully in the investigation of a diverse array of human diseases. The potential of high-throughput expression analysis to improve our understanding of the pathogenesis of PAH is highlighted in this review. Proteomic studies of PAH and pulmonary vascular diseases in general have been little utilized thus far. To date, such studies are few and no consistent biomarker has emerged from studies of either plasma or blood cells from idiopathic pulmonary arterial hypertension (IPAH) patients. The studies of both lung tissue and lymphocytes are perhaps more revealing and suggest that changes in the cytoskeletal machinery may play a role in the pathogenesis of idiopathic pulmonary arterial hypertension. The oncology literature has demonstrated the utility of gene microarray analysis to predict important outcomes such as response to therapy and survival. It is likely that in the near future, gene microarrays and proteomic analyses will also be employed in a pharmacogenomics approach in PAH, helping to identify the most appropriate therapies for individual patients.

Original languageEnglish (US)
Pages (from-to)467-483
Number of pages17
JournalComprehensive Physiology
Volume1
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Genomics
Vascular Diseases
Pulmonary Hypertension
Proteomics
Lung Diseases
Microarray Analysis
Blood Cells
Biomarkers
Technology
Pharmacogenetics
Plasma Cells
Transcriptome
Genes
Research Personnel
Lymphocytes
RNA
Pathology
Biopsy
Lung
Survival

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Genomics and proteomics of pulmonary vascular disease. / Geraci, Mark; Meyrick, Barbara.

In: Comprehensive Physiology, Vol. 1, No. 1, 01.2011, p. 467-483.

Research output: Contribution to journalArticle

Geraci, Mark ; Meyrick, Barbara. / Genomics and proteomics of pulmonary vascular disease. In: Comprehensive Physiology. 2011 ; Vol. 1, No. 1. pp. 467-483.
@article{e94cf9ccc76e4575b9fb9fbe915a0dc4,
title = "Genomics and proteomics of pulmonary vascular disease",
abstract = "Study of RNA and proteins in cells of both normal and diseased tissues is providing researchers with new knowledge of disease pathologies. While still in its early stages, high-throughput expression analysis is improving our understanding of the pathogenesis of pulmonary arterial hypertension (PAH). While many studies have used microarray and proteomic analyses as {"}hypothesisgenerating{"} tools, the technologies also have potential to identify and quantify biomarkers of disease. To date, many of the published studies have examined gene expression profiles of tissue biopsies, others have utilized cells from peripheral blood. Microarray technology has been employed successfully in the investigation of a diverse array of human diseases. The potential of high-throughput expression analysis to improve our understanding of the pathogenesis of PAH is highlighted in this review. Proteomic studies of PAH and pulmonary vascular diseases in general have been little utilized thus far. To date, such studies are few and no consistent biomarker has emerged from studies of either plasma or blood cells from idiopathic pulmonary arterial hypertension (IPAH) patients. The studies of both lung tissue and lymphocytes are perhaps more revealing and suggest that changes in the cytoskeletal machinery may play a role in the pathogenesis of idiopathic pulmonary arterial hypertension. The oncology literature has demonstrated the utility of gene microarray analysis to predict important outcomes such as response to therapy and survival. It is likely that in the near future, gene microarrays and proteomic analyses will also be employed in a pharmacogenomics approach in PAH, helping to identify the most appropriate therapies for individual patients.",
author = "Mark Geraci and Barbara Meyrick",
year = "2011",
month = "1",
doi = "10.1002/cphy.c100031",
language = "English (US)",
volume = "1",
pages = "467--483",
journal = "Comprehensive Physiology",
issn = "2040-4603",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Genomics and proteomics of pulmonary vascular disease

AU - Geraci, Mark

AU - Meyrick, Barbara

PY - 2011/1

Y1 - 2011/1

N2 - Study of RNA and proteins in cells of both normal and diseased tissues is providing researchers with new knowledge of disease pathologies. While still in its early stages, high-throughput expression analysis is improving our understanding of the pathogenesis of pulmonary arterial hypertension (PAH). While many studies have used microarray and proteomic analyses as "hypothesisgenerating" tools, the technologies also have potential to identify and quantify biomarkers of disease. To date, many of the published studies have examined gene expression profiles of tissue biopsies, others have utilized cells from peripheral blood. Microarray technology has been employed successfully in the investigation of a diverse array of human diseases. The potential of high-throughput expression analysis to improve our understanding of the pathogenesis of PAH is highlighted in this review. Proteomic studies of PAH and pulmonary vascular diseases in general have been little utilized thus far. To date, such studies are few and no consistent biomarker has emerged from studies of either plasma or blood cells from idiopathic pulmonary arterial hypertension (IPAH) patients. The studies of both lung tissue and lymphocytes are perhaps more revealing and suggest that changes in the cytoskeletal machinery may play a role in the pathogenesis of idiopathic pulmonary arterial hypertension. The oncology literature has demonstrated the utility of gene microarray analysis to predict important outcomes such as response to therapy and survival. It is likely that in the near future, gene microarrays and proteomic analyses will also be employed in a pharmacogenomics approach in PAH, helping to identify the most appropriate therapies for individual patients.

AB - Study of RNA and proteins in cells of both normal and diseased tissues is providing researchers with new knowledge of disease pathologies. While still in its early stages, high-throughput expression analysis is improving our understanding of the pathogenesis of pulmonary arterial hypertension (PAH). While many studies have used microarray and proteomic analyses as "hypothesisgenerating" tools, the technologies also have potential to identify and quantify biomarkers of disease. To date, many of the published studies have examined gene expression profiles of tissue biopsies, others have utilized cells from peripheral blood. Microarray technology has been employed successfully in the investigation of a diverse array of human diseases. The potential of high-throughput expression analysis to improve our understanding of the pathogenesis of PAH is highlighted in this review. Proteomic studies of PAH and pulmonary vascular diseases in general have been little utilized thus far. To date, such studies are few and no consistent biomarker has emerged from studies of either plasma or blood cells from idiopathic pulmonary arterial hypertension (IPAH) patients. The studies of both lung tissue and lymphocytes are perhaps more revealing and suggest that changes in the cytoskeletal machinery may play a role in the pathogenesis of idiopathic pulmonary arterial hypertension. The oncology literature has demonstrated the utility of gene microarray analysis to predict important outcomes such as response to therapy and survival. It is likely that in the near future, gene microarrays and proteomic analyses will also be employed in a pharmacogenomics approach in PAH, helping to identify the most appropriate therapies for individual patients.

UR - http://www.scopus.com/inward/record.url?scp=84861983248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861983248&partnerID=8YFLogxK

U2 - 10.1002/cphy.c100031

DO - 10.1002/cphy.c100031

M3 - Article

C2 - 23737182

AN - SCOPUS:84861983248

VL - 1

SP - 467

EP - 483

JO - Comprehensive Physiology

JF - Comprehensive Physiology

SN - 2040-4603

IS - 1

ER -